SABS logo

SABS
SAB Biotherapeutics Inc

1,719
Mkt Cap
$191.07M
Volume
197,594.00
52W High
$6.60
52W Low
$1.23
PE Ratio
-1.40
SABS Fundamentals
Price
$3.75
Prev Close
$3.83
Open
$3.83
50D MA
$3.97
Beta
0.76
Avg. Volume
889,070.39
EPS (Annual)
-$0.7944
P/B
1.18
Rev/Employee
$0.00
$138.77
Loading...
Loading...
News
all
press releases
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Rodman & Renshaw
Rodman & Renshaw initiated coverage on SAB Biotherapeutics in a report on Thursday. They issued a "buy" rating and a $13.00 target price on the stock...
MarketBeat·10d ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a large increase in short interest in March. As of March 13th, there was short interest totaling 1,953,472 shares, an increase of 21.1% from the February 26th total of 1,613,558 shares. Based on an average daily volume of 918,838...
MarketBeat·11d ago
News Placeholder
SAB Biotherapeutics (SABS) to Release Earnings on Friday
SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q4 2025 earnings before the market opens on Friday, March 27. (View Earnings Report at...
MarketBeat·23d ago
News Placeholder
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update
SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat·26d ago
News Placeholder
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS
Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·28d ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen lowered SAB Biotherapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·29d ago
News Placeholder
Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00
Chardan Capital boosted their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday...
MarketBeat·1mo ago
News Placeholder
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright
HC Wainwright reduced their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf
SAB Biotherapeutics (NASDAQ:SABS) used an appearance at Oppenheimer's 36th Annual Healthcare Life Sciences Conference to outline its strategy in type 1 diabetes (T1D), emphasizing development of a...
MarketBeat·1mo ago
<
1
2
...
>

Latest SABS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.